These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 1998794)

  • 1. Effects of withdrawing erythropoietin.
    Taylor JE; Henderson IS; Mactier RA; Stewart WK
    BMJ; 1991 Feb; 302(6771):272-3. PubMed ID: 1998794
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure.
    Muirhead N; Hodsman AB
    Nephrol Dial Transplant; 1990; 5(3):232-4. PubMed ID: 2113653
    [No Abstract]   [Full Text] [Related]  

  • 5. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT; Sherwood RA; Hillis A; Peters TJ
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 8. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
    Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
    Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
    [No Abstract]   [Full Text] [Related]  

  • 9. Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
    Jones-Lecointe A; Green PJ; Lee HA
    Clin Lab Haematol; 1991; 13(3):251-3. PubMed ID: 1794227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 11. Association between haemoglobin and neopterin concentrations in haemodialysis patients treated with erythropoietin.
    Diez-Ruiz A; Weiss G; Artner-Dworzak E; Dittrich PV; Wachter H; Fuchs D
    Eur J Haematol; 1993 Sep; 51(3):175-6. PubMed ID: 8405333
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant human erythropoietin in patients on peritoneal dialysis.
    Bargman J
    Perit Dial Int; 1989; 9(4):245-6. PubMed ID: 2488375
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemoglobin levels, quality of life, and survival.
    Sadler JH; Meyer KB
    Nephrol News Issues; 2007 Aug; 21(9):42-3. PubMed ID: 17722853
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism.
    Garcia-Canton C; Palomar R; Moreno A; Toledo A; Suria S; Esparza N; Rossique P; Checa MD
    Nephron; 1996; 74(2):444-5. PubMed ID: 8893180
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
    BMJ; 1990 Mar; 300(6724):573-8. PubMed ID: 2108751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 17. [Advances in therapy of renal anemia: darbepoetin alfa].
    Schaefer R
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietin use in a Jehovah's Witness patient.
    Walton T; Macon EJ
    Ann Pharmacother; 2002 Apr; 36(4):729-30. PubMed ID: 11936087
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
    Hussein MM; Mooij JM; Roujouleh H
    Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.